Krilogy Financial LLC Has $261,000 Position in Biogen Inc (NASDAQ:BIIB)

Krilogy Financial LLC raised its stake in shares of Biogen Inc (NASDAQ:BIIB) by 153.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 835 shares of the biotechnology company’s stock after purchasing an additional 505 shares during the quarter. Krilogy Financial LLC’s holdings in Biogen were worth $261,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of BIIB. Janus Henderson Group PLC increased its holdings in shares of Biogen by 4,585.3% during the 2nd quarter. Janus Henderson Group PLC now owns 1,445,560 shares of the biotechnology company’s stock worth $392,265,000 after purchasing an additional 1,414,707 shares during the period. Ameriprise Financial Inc. increased its stake in Biogen by 35.1% in the third quarter. Ameriprise Financial Inc. now owns 2,309,394 shares of the biotechnology company’s stock valued at $723,142,000 after acquiring an additional 600,384 shares during the period. FMR LLC increased its stake in Biogen by 10.1% in the second quarter. FMR LLC now owns 6,104,026 shares of the biotechnology company’s stock valued at $1,656,390,000 after acquiring an additional 561,436 shares during the period. Bank of New York Mellon Corp increased its stake in Biogen by 24.0% in the third quarter. Bank of New York Mellon Corp now owns 2,325,987 shares of the biotechnology company’s stock valued at $728,314,000 after acquiring an additional 450,207 shares during the period. Finally, TIAA CREF Investment Management LLC increased its stake in Biogen by 28.8% in the second quarter. TIAA CREF Investment Management LLC now owns 1,906,820 shares of the biotechnology company’s stock valued at $517,434,000 after acquiring an additional 426,821 shares during the period. Institutional investors own 88.11% of the company’s stock.

In related news, Director Alexander J. Denner bought 30,000 shares of Biogen stock in a transaction dated Wednesday, November 29th. The shares were bought at an average cost of $317.36 per share, for a total transaction of $9,520,800.00. Following the completion of the transaction, the director now owns 10,029 shares of the company’s stock, valued at $3,182,803.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michel Vounatsos bought 780 shares of Biogen stock in a transaction dated Saturday, December 29th. The shares were bought at an average price of $320.55 per share, for a total transaction of $250,029.00. Following the completion of the transaction, the chief executive officer now directly owns 4,879 shares of the company’s stock, valued at approximately $1,563,963.45. The disclosure for this purchase can be found here. Insiders have bought 31,560 shares of company stock worth $10,020,858 over the last quarter. 0.25% of the stock is owned by company insiders.

A number of analysts recently weighed in on BIIB shares. Royal Bank of Canada reissued a “hold” rating and issued a $321.00 target price on shares of Biogen in a research note on Tuesday, December 5th. SunTrust Banks reissued a “buy” rating and issued a $354.00 target price on shares of Biogen in a research note on Tuesday, October 24th. Canaccord Genuity started coverage on shares of Biogen in a research note on Friday, October 27th. They issued a “hold” rating and a $340.00 target price on the stock. BMO Capital Markets raised shares of Biogen from a “market perform” rating to an “outperform” rating and set a $377.00 target price on the stock in a research note on Wednesday, October 25th. Finally, Mizuho reissued a “neutral” rating and issued a $319.00 target price (up previously from $274.00) on shares of Biogen in a research note on Wednesday, September 13th. Ten investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $350.13.

Shares of Biogen Inc (NASDAQ:BIIB) traded up $15.60 during mid-day trading on Tuesday, hitting $334.17. 1,417,700 shares of the stock were exchanged, compared to its average volume of 1,030,000. Biogen Inc has a 12 month low of $244.28 and a 12 month high of $348.84. The firm has a market capitalization of $70,670.00, a price-to-earnings ratio of 20.49, a price-to-earnings-growth ratio of 1.99 and a beta of 0.73. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.19 and a quick ratio of 1.90.

Biogen (NASDAQ:BIIB) last announced its earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $5.70 by $0.61. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The company had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same period in the prior year, the business earned $5.19 earnings per share. Biogen’s quarterly revenue was up 4.1% on a year-over-year basis. equities research analysts anticipate that Biogen Inc will post 22.01 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Krilogy Financial LLC Has $261,000 Position in Biogen Inc (NASDAQ:BIIB)” was first reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.truebluetribune.com/2018/01/03/biogen-inc-biib-holdings-lifted-by-krilogy-financial-llc.html.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply